ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
暂无分享,去创建一个
Yusuke Nakamura | T. Tsunoda | K. Chayama | H. Kumada | H. Ochi | T. Maekawa | H. Abe | Yasufumi Hayashida | C. N. Hayes | Rikita Nakano | M. Kubo
[1] Jacques Fellay,et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.
[2] A. Koike,et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.
[3] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[4] Yoshiyuki Suzuki,et al. Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads , 2009, Digestive Diseases and Sciences.
[5] H. Tajiri,et al. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment , 2009, Journal of Gastroenterology.
[6] V. Armstrong,et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. , 2005, Clinical chemistry.
[7] E. Kuipers,et al. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. , 2005, Gut.
[8] H. Nomura,et al. Factors contributing to ribavirin‐induced anemia , 2004, Journal of gastroenterology and hepatology.
[9] R. Gearry,et al. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. , 2004, Pharmacogenetics.
[10] Yoshiyuki Suzuki,et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C , 2004, Journal of Gastroenterology.
[11] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[12] A. Bruchfeld,et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin‐induced anaemia , 2004, Journal of viral hepatitis.
[13] Yusuke Nakamura,et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis , 2003, Nature Genetics.
[14] R. Hegele,et al. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency , 2002, Journal of Human Genetics.
[15] J. Sanderson,et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency , 2002, Human Genetics.
[16] S. Gabriel,et al. The Structure of Haplotype Blocks in the Human Genome , 2002, Science.
[17] M. Manns,et al. Peginterferon alfa-2b plus ribavirin for chronic hepatitis , 2002, The Lancet.
[18] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[19] Yusuke Nakamura,et al. A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.
[20] M. Vos,et al. Factors influencing ribavirin-induced hemolysis. , 2001, Journal of hepatology.
[21] G. Fattovich,et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage , 2000, Hepatology.
[22] C. Gil,et al. Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C , 1995, Hepatology.
[23] J. Hoofnagle,et al. Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.
[24] B. S. Vanderheiden. Genetic studies of human erythrocyte inosine triphosphatase , 1969, Biochemical Genetics.
[25] J. Sanderson,et al. The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. , 2007, Biochimica et biophysica acta.
[26] Y. Jeong,et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .